biostudies-arrayexpressUnknownTranscriptomicsGenomicsProteomicsPetr Nazarovtranscription profiling by arrayHomo sapiensHomo sapienshttps://www.ebi.ac.uk/biostudies/studies/E-MTAB-16324Peripheral blood from 70 individuals (31 CML patients who subsequently relapsed after discontinuation of tyrosine kinase inhibitors (TKI) treatment, 29 CML patients who maintained treatment-free remission, and 10 healthy donors) was profiled to investigate transcriptional programs associated with sustained control versus relapse. Samples from CML patients were collected on the last day of TKI treatment within the EURO-SKI trial, and leukocytes were isolated for RNA extraction. Genome-wide expression profiling was performed using Clariom D microarrays (Applied Biosystems). The resulting dataset aims to define peripheral blood molecular signatures and biomarkers that predict treatment-free remission in CML.biostudies-arrayexpressNucleic Acid Extraction - RNA was extracted using a TRIzol-based protocol. Total RNA quantification was performed using the Nanodrop (Thermo Scientific). Gene-level expression microarray-based analysis has been performed throughout the human Clariom™ D assay (Applied Biosystems) according to the manufacturer’s instructions.Labeling - Applied Biosystems Clariom™ D (human) arrays were prepared in accordance with the standard protocol.Hybridization - Applied Biosystems Clariom™ D (human) arrays were prepared in accordance with the standard protocol.Sample Treatment - Peripheral blood was collected at the last day of TKI intake (=baseline).Sample Collection - Peripheral venous blood samples were obtained from 60 adult patients with chronic myeloid leukemia (CML) on the last day of tyrosine kinase inhibitor (TKI) treatment, after obtaining written informed consent and approval from the ethics committee. Additionally, 10 adult volunteers donated blood as a healthy control group. Leukocyte-enriched cell fractions were prepared using density-gradient separation and erythrocyte lysis, washed in phosphate-buffered saline, pelleted, and transferred into RNA-stabilizing reagent.Scaning - Applied Biosystems Clariom™ D (human) arrays were prepared in accordance with the standard protocol.MIAME ScoreRaw DataOrganizationAssays and DataMAGE-TAB FilesArray DesignsSébastien RinaldettiPetr NazarovMaryna ChepelevaData Transformation - Microarray data were normalized and summarized using the SST-RMA algorithm in the Transcriptome Analysis Console (TAC v.4.0.3.14). Further analysis was performed in R/Bioconductor.falseTreatment-free remission and relapse in chronic myeloid leukaemia (CML) patientsPeripheral blood from 70 individuals (31 CML patients who subsequently relapsed after discontinuation of tyrosine kinase inhibitors (TKI) treatment, 29 CML patients who maintained treatment-free remission, and 10 healthy donors) was profiled to investigate transcriptional programs associated with sustained control versus relapse. Samples from CML patients were collected on the last day of TKI treatment within the EURO-SKI trial, and leukocytes were isolated for RNA extraction. Genome-wide expression profiling was performed using Clariom D microarrays (Applied Biosystems). The resulting dataset aims to define peripheral blood molecular signatures and biomarkers that predict treatment-free remission in CML.2026-06-01T00:00:00Z2026-06-01T19:29:29.767Z2025-12-02T21:04:56.183ZE-MTAB-16324EFO_0002768EFO_0002944EFO_0003814EFO_0003813EFO_0005518EFO_0003816EFO_0003815EFO_0003969